Enanta Reports New Macrolide-Related Drug Class, Bicyclolides, to Combat Hospital and Community Acquired Superbug Infections, Including MRSA

Data Presented at the 10th Annual Superbugs and Superdrugs Conference on


Apr 10, 2008, 01:00 ET from Enanta Pharmaceuticals

    WATERTOWN, Mass., April 10 /PRNewswire/ -- Enanta Pharmaceuticals, a
 leader in the development of small molecule anti-infective drugs, today
 announced the presentation of their breakthrough research program to
 evaluate a new macrolide-related drug class, Bicyclolides, in the treatment
 of methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant
 Enterococcus (VRE), and other gram-positive infection pathogens. Enanta's
 Bicyclolides have also demonstrated strong activity against MRSA strains
 resistant to vancomycin, Zyvox(R) (linezolid), and CUBICIN(R) (daptomycin).
     The oral presentation, "New Bicyclolides Active Against MRSA and VRE,"
 was presented today during the 10th Annual Superbugs and Superdrugs
 Conference in London, England.
     "Previously, MRSA infection was a problem mainly for patients treated
 in hospitals," said Robert Moellering, M.D., a professor of medicine at
 Harvard Medical School and Beth Israel Deaconess Medical Center. "Now we're
 seeing MRSA in the general community, creating a tremendous need for a new
 class of antibiotics with improved safety profile and more convenient
 administration for use within both hospital as well as community settings.
 The growing problem of bacterial resistance to many existing drugs also
 necessitates the development of new classes of compounds to fight the
     "Pre-clinical research on these new Bicyclolide compounds revealed
 activity against MRSA and VRE, even against highly drug-resistant MRSA
 strains. This was an unexpected finding, because traditional macrolides do
 not work against these bacteria," explained Yat Sun Or, Ph.D., Senior Vice
 President of Research and Development at Enanta. "These results are also
 very exciting, because we have observed activity as good as
 intravenously-administered vancomycin or Zyvox(R) with oral once-a-day
 dosing levels of the Bicyclolides. The convenience of oral administration
 and the safety profile of macrolides as a class represent patient and
 pharmacoeconomic benefits that could be potentially quite significant,
 making this program a worthwhile endeavor."
     About Enanta's Bicyclolide research program
     Bicyclolides posses a reengineered back-bone structure of traditional
 macrolides, whose benefits include the potential for oral and intravenous
 administration and limited side-effects. The discovery of Bicyclolides'
 effectiveness against MRSA and VRE infections is part of Enanta's broad
 antibiotic research program. Enanta has applied several research strategies
 to develop these new classes of antibiotics, including innovative medicinal
 chemistry approaches to create novel and proprietary chemical structures.
 Enanta has applied its chemistry approach to create promising product
 pipelines and a vast intellectual property estate.
     About MRSA
     More than 130,000 people each year need hospital care for MRSA,
 according to the Centers for Disease Control and Prevention. Staphylococcus
 aureus is a bacterium that can live harmlessly on human skin and is found
 in the nose of 20 to 40 percent of healthy individuals, but can sometimes
 cause infections when exposed to broken skin. MRSA is a particular type of
 the bacteria that has developed resistance to many antibiotics, including
 methicillin, making it difficult to treat. Currently, the antibiotic drugs
 typically administered to MRSA patients are intravenous. This method is
 expensive and inconvenient, especially for those who acquired the infection
 in the community and must seek hospital treatment for lengthy intravenous
     About Enanta
     Enanta Pharmaceuticals is a research and development company that uses
 its novel chemistry approach and drug discovery capabilities to create best
 in class small molecule drugs in the anti-infective field. At the heart of
 Enanta is its commitment to innovative chemistry that surpasses traditional
 medicinal chemistry approaches. Enanta is developing novel protease and
 polymerase inhibitors targeted against the Hepatitis C virus (HCV).
 Additionally, the Company has created a new class of macrolide antibiotics,
 called Bicyclolides, which overcome bacterial resistance. Antibacterial
 focus areas include superbugs, respiratory tract infections, and
 intravenous and oral treatments for hospital and community MRSA. Enanta is
 a privately held company with offices in Watertown, MA. More information
 about the company can be found at www.enanta.com .
     Zyvox is a registered trademark of Pfizer Inc. and CUBICIN is a
 registered trademark of Cubist Pharmaceuticals, Inc.
Enanta Contacts For Enanta Investor Relations, please contact: Paul Mellett 617-607-0761 For Enanta Public Relations, please contact MacDougall Biomedical Communications: Kari Watson 781-235-3060 kwatson@macbiocom.com

SOURCE Enanta Pharmaceuticals